Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Estetrol Approvals Mark 'Turning Point' For Mithra

Also Plans Further Launches Of Myring Generic Rival To NuvaRing

Executive Summary

Recent Canadian, European and US endorsements of Mithra’s estetrol-based Estelle novel oral contraceptive mark a “turning point” for the Belgian firm, which has also seen success with its Myring generic rival to NuvaRing for which it expects to see further launches this year.

You may also be interested in...



Who’s Hired? Stada Appoints New Biosimilars Head

Stada has welcomed former Novo Nordisk executive Erin Federman into its ranks as she steps into the role of global commercial head of biosimilars. Organizations such as the Association for Accessible Medicines, Granules India, Synthon, Taro and Mayne have also appointed new senior staff members in recent months.

Who’s Hired? Another Viatris Executive Joins Neuraxpharm

Neuraxpharm has appoints Viatris’ head of finance in Germany as its new commercial central region officer and country manager to strengthen its position in the German market, while Stada has hired a new head of consumer health in Germany. Meanwhile, the AAM has made multiple key appointments and Hyloris, Siegfried and Mayne Pharma have made top-level additions.

Regulators Decide On EU Marketing For 'Game-Changing' Contraceptive

Mithra’s combined oral contraceptive Estelle includes estetrol, the first compound in the contraceptive area to be designated a new active substance in Europe in over 80 years.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel